

CONTENTS

I. A HISTORICAL NOTE

Two thousand years of fibrinogen research and evidence for fibrin being the first protein A. Henschen	3
---	---

II. GENE ANALYSIS

Fibrinogen evolution - The structure and evolution of fibrinogen: The coiled coil region D.M. Fowlkes, N.T. Mullis, C.M. Comeau and G.R. Crabtree	11
Absence of gross defect of fibrinogen genes in one patient with congenital afibrinogenemia G. Courtois, G. Uzan, Z. Assouline, G. Marguerie and A. Kahn	23

III. FIBRINOGEN-FIBRIN CONVERSION

Fibrinogen to fibrin - an overview B. Blombäck	33
Fibrin-specific monoclonal antibodies are elicited by immunization with a synthetic fibrin-like peptide G.R. Matsueda, K.Y. Hui and E. Haber	43
Enhancement of fibrin polymerization by active site-inhibited thrombin M. Kaminski and J. McDonagh	51
Peptides released from human fibrinogen by thrombic enzymes J. Harenberg, J.X. de Vries and S. Waibel	65
The analysis of fibrinopeptide release from S-carboxymethylated fibrinogen chains using high-performance liquid chromatography C. Southan and A. Henschen	73
Modification of the fibrin α -chain by dipeptidyl peptidase IV R. Mentlein, G. Struckhoff and E. Heymann	83

IV. FIBRINOGEN-FIBRIN INTERACTION

Analysis of composition of soluble fibrinogen/fibrin complexes by differential ultracentrifugation J.R. Shainoff	91
---	----

Reversible interactions of fibrin and fibrinogen: an ultracentrifugation study K.T. Preissner, J. Rötter, E. Selmayr, H. Fasold and G. Müller-Berghaus	101
---	-----

V. NORMAL FIBRINOGEN VARIANTS

Evidence that the amount of heparin precipitable fraction is influenced by fibrinogen quality B. Holm and H.C. Godal	113
---	-----

The location of a second in vivo phosphorylation site in the A α -chain of human fibrinogen H.H. Seydewitz, C. Kaiser and I. Witt	121
---	-----

Evidence that the γ chain population of human platelet fibrinogen lacks the γ' variant that is present in plasma fibrinogen M.W. Mosesson, G.A. Homandberg and D.L. Amrani	133
---	-----

Differences and similarities between human adult and fetal fibrinogen fragments D ₁ D.K. Galanakis	147
--	-----

VI. ABNORMAL FIBRINOGEN VARIANTS

Functional defects in abnormal fibrinogens N. Carrell and J. McDonagh	155
--	-----

Study of 10 cases of congenital dysfibrinogenemia: clinical and molecular biological aspects J. Soria, C. Soria, M. Samama and J. Caen	165
---	-----

Fibrinogens Sydney I and II, a kinetic study of (His ¹⁶)FPA cleavage and its effect on FPB cleavage C. Southan, A. Henschen and D.A. Lane	185
--	-----

Fibrinogens London I - IV, Manchester, Sydney I and II. Cleavage of fibrinopeptides by thrombin and expression of their polymerisation abnormalities D.A. Lane, H. Ireland, E. Thompson, C. Southan and A. Henschen	197
--	-----

Aspects of evaluation of fibrinogen Stony Brook - A defect resulting in failure to release fibrinopeptide A D.K. Galanakis and A. Henschen	207
Fibrinogen Tokyo II: An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules M. Matsuda, C. Nakamikawa, M. Baba and K. Morimoto	213
Fibrinogen Milan II: A congenital dysfibrinogenemia with a defective clotting by thrombin, normal clotting by arvin, reptilase and prothrombin-staphylocoagulase complex, associated with thrombotic episodes F. Haverkate, J. Koopman, C. Kluft, P.M. Mannucci, A. d'Angelo and R.M. Bertina	223
Preliminary report concerning two new cases of congenital dysfibrinogenemia (Homburg II and Homburg III) C. Miyashita, J. Schwamborn, G. von Blohn, E. Wenzel and P. Hellstern	237
The effect of sodium citrate on fibrin polymerisation in patients with liver disease J.L. Francis, N.J. Watson, V.J. Simmonds and D.J. Armstrong	247
VII. FIBRINOGEN DEGRADATION PRODUCTS	
Studies of the proteolytic fragments of the C-terminal portion of the α -chain of human fibrinogen E. Mihalyi	257
Biodistribution of human fibrinogen-derived peptides in rabbits J. Harenberg, G. Stehle, S. Waibel, M. Eisenhut and H.-J. Hermann	271
Structure-function studies on a vasoactive pentapeptide derived from plasmin degradation of human fibrin(ogen) R. Wallin, K. Saldeen and T. Saldeen	279
Purification and characteristics of a vasoactive peptide derived from elastase degradation of human fibrin(ogen) R. Wallin, K. Saldeen, M. Belew, K. Ohlsson and T. Saldeen	289
Relation of crosslinked to non crosslinked fibrin derivatives in tumor ascites compared to cirrhosis ascites R. Hafter, W. Klaubert, R. Gollwitzer, R. von Hugo and H. Graeff	301

VIII. INTERACTION WITH PLASMINOGEN AND ITS ACTIVATOR

Study of the interaction between plasminogen and fibrinogen degradation products using immunoenzymological assay

J. Soria, C. Soria, F. Dunn, K. Deguchi, M. Mirshahi, R. Lijnen, W. Nieuwenhuizen, F. Haverkate, M. Samama and J. Caen

313

Fibrin and plasminogen structures involved in the tissue-type plasminogen activator catalyzed activation of plasminogen

J. Verheijen, W. Nieuwenhuizen, D. Traas, G. Chang and B. Hoegee-de Nobel

323

Kinetics of the tissue-type plasminogen activator-mediated activation of plasminogen. Influence of CNBr fibrin(ogen) fragment FCB-2 and different forms of plasminogen

W. Nieuwenhuizen, M. Voskuilen, D.W. Traas, B. Hoegee-de Nobel and J.H. Verheijen

331

IX. INTERACTION WITH CELLS

Structural characterization of the recognition site for platelet receptors on human fibrinogen

J. Hawiger, M. Kloczewiak, S. Timmons and T.J. Lukas

345

Binding of fibrinogen to ADP-treated platelets:

Importance of the A α -chain

E.I.B. Peerschke and D.K. Galanakis

369

Inhibition of fibrinogen binding to activated platelets by oligoamines

G. Agam, R. Luria, L. Shoshani and A. Livne

379

Specific interaction between fibrinogen-fibrin and endothelial cells

E. Dejana, L.R. Languino, V.M. Dauden, G. Balconi and G. Marguerie

387

Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells

K. Tanaka and K. Watanabe

395

Interaction of fibrin with malignant melanoma cells in long term culture

M. Jeleńska, M. Kopeć, M. Rochowska and H. Skurzak

405

AUTHOR INDEX

413

SUBJECT INDEX

415